Want to see WST full AI Analyst Report?
WST Stock Chart & Stats
$273.73
$0.15(0.05%)
At close: 4:00 PM EST
$273.73
$0.15(0.05%)
Day’s Range― - ―
52-Week Range$211.10 - $367.66
Previous CloseN/A
Volume102.64K
Average Volume (3M)740.80K
Market Cap
$25.31B
Enterprise Value$17.95K
Total Cash (Recent Filing)$521.40M
Total Debt (Recent Filing)$316.20M
Price to Earnings (P/E)46.9
Beta0.76
Next Earnings
Jul 23, 2026EPS Estimate
2.08Next Dividend Ex-DateN/A
Dividend Yield0.25%
Share Statistics
EPS (TTM)7.52
Shares Outstanding70,647,600
10 Day Avg. Volume642,093
30 Day Avg. Volume740,804
Financial Highlights & Ratios
PEG Ratio33.99
Price to Book (P/B)6.26
Price to Sales (P/S)6.47
P/FCF Ratio42.42
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$399.63Price Target Upside45.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)8.62
Revenue Forecast (FY)$3.33B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a sizeable equity base provide durable financial flexibility: supports sustained capex, R&D and the $1B repurchase program while insulating the company from input cost shocks and enabling disciplined M&A or customer support through cyclical demand swings.
High-Value Product GrowthHVP and GLP-1 driven demand represents structural growth: high-value mix supports pricing power and margins, recurring qualification cycles lock in multi-year revenue streams, and secular tailwinds (GLP-1 expansion, biologics) sustain above-market organic growth for months to years.
Long-Term Strategic PartnershipA renewed 10-year cross-license and distribution pact secures technology sharing and global market access. This institutionalizes product development collaboration and stable routes-to-market, reducing commercial execution risk and supporting durable international sales growth and product availability.
Bears Say
Margin SustainabilityAlthough margins remain healthy, they have receded from prior peak levels. Persistent mix shifts, ramp costs and commodity pressure could cap operating margin upside and weigh on long-term ROE and free cash flow unless efficiencies or pricing fully offset these secular and structural cost pressures.
Site Qualification Lead Times6–12 month site qualification windows limit responsiveness to sudden volume ramps and constrain multi-site reallocation. This structural capacity lag can hinder the company's ability to capture fast-growing demand pockets, forcing higher inventory or delayed revenues during customer scale-ups.
Contract Roll-Off & Cash TimingContract expirations and customer-specific revenue lapses expose the business to step-downs in reported sales; coupled with AR-driven cash timing effects noted in Q1, this underscores structural revenue concentration and working-capital variability that can pressure operating cash flow and planning.
West Pharmaceutical Services News
WST FAQ
What was West Pharmaceutical Services, Inc.’s price range in the past 12 months?
West Pharmaceutical Services, Inc. lowest stock price was $211.10 and its highest was $367.66 in the past 12 months.
What is West Pharmaceutical Services, Inc.’s market cap?
West Pharmaceutical Services, Inc.’s market cap is $25.31B.
When is West Pharmaceutical Services, Inc.’s upcoming earnings report date?
West Pharmaceutical Services, Inc.’s upcoming earnings report date is Jul 23, 2026 which is in 2 days.
How were West Pharmaceutical Services, Inc.’s earnings last quarter?
West Pharmaceutical Services, Inc. released its earnings results on Apr 23, 2026. The company reported $2.13 earnings per share for the quarter, beating the consensus estimate of $1.678 by $0.452.
Is West Pharmaceutical Services, Inc. overvalued?
According to Wall Street analysts West Pharmaceutical Services, Inc.’s price is currently Undervalued.
Does West Pharmaceutical Services, Inc. pay dividends?
West Pharmaceutical Services, Inc. pays a Quarterly dividend of $0.22 which represents an annual dividend yield of 0.25%. See more information on West Pharmaceutical Services, Inc. dividends here
What is West Pharmaceutical Services, Inc.’s EPS estimate?
West Pharmaceutical Services, Inc.’s EPS estimate is 2.08.
How many shares outstanding does West Pharmaceutical Services, Inc. have?
West Pharmaceutical Services, Inc. has 70,647,600 shares outstanding.
What happened to West Pharmaceutical Services, Inc.’s price movement after its last earnings report?
West Pharmaceutical Services, Inc. reported an EPS of $2.13 in its last earnings report, beating expectations of $1.678. Following the earnings report the stock price went up 12.86%.
Which hedge fund is a major shareholder of West Pharmaceutical Services, Inc.?
Currently, no hedge funds are holding shares in WST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
West Pharmaceutical Services Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$399.63 (45.99% Upside)
$399.63 (45.99% Upside)
Blogger Sentiment
Bullish
WST Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 925.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 10.3%
Last 30 Days ▲ 10.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.61%
12-Months-Change
Fundamentals
Return on Equity
0.25%
Trailing 12-Months
Asset Growth
13.59%
Trailing 12-Months
Company Description
West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
WST Revenue Breakdown
81.07% Proprietary Products
18.93% Contract-Manufactured Products
0.00% Intersegment sales elimination
WST Stock 12 Month Forecast
Average Price Target
$399.63
▲(45.99% Upside)
Technical Analysis
Ownership Overview
0.55% Insiders
26.42% Mutual Funds
0.78% Other Institutional Investors
41.71% Public Companies and
Individual Investors